Source: ERJ Open Res, 5 (1) 00252-2018; 10.1183/23120541.00252-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Holly R. Keir, Christopher J. Fong, Megan L. Crichton, Philip Barth, Eric Chevalier, Gill Brady, Gwen Kennedy, Johann Zimmermann, Piet L.B. Bruijnzeel, Alison J. Dicker, James D. Chalmers. Personalised anti-inflammatory therapy for bronchiectasis and cystic fibrosis: selecting patients for controlled trials of neutrophil elastase inhibition. ERJ Open Res, 5 (1) 00252-2018; 10.1183/23120541.00252-2018

Member's Comments

No comment yet.

Related content which might interest you: Comparison of different techniques to evaluate active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019 Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 α1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients Source: Eur Respir J 2007; 29: 240-250 Year: 2007 Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis}, Source: Eur Respir J 2012; 40: 969-976 Year: 2012 Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Inhaled heparin in cystic fibrosis Source: Eur Respir J 2006; 27: 354-358 Year: 2006 Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009 The effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis- A randomised controlled trial Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation and chronic care Year: 2017 An anti-inflammatory effect of azithromycin in cystic fibrosis Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010 Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial Source: Eur Respir J, 57 (1) 2000348; 10.1183/13993003.00348-2020 Year: 2021 The concept of cystic fibrosis pulmonary exacerbation in clinical medicine and as a trial end-point Source: Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art Year: 2008 Evaluation of neutrophils phagocytosis and killing in pulmonary cystic fibrosis patients Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 Neutrophil functional activity of patients with cystic fibrosis Source: Annual Congress 2008 - Cystic fibrosis: factors affecting lung health Year: 2008 Neutrophil functional activity of patients with cystic fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004 Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? Source: Annual Congress 2008 - Cystic fibrosis: a disease with many aspects Year: 2008 Contemporary surgical issues in NSCLC treatment Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer Year: 2007 Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 342s Year: 2002